In the last trading session, 7.69 million shares of the Moderna Inc. (NASDAQ:MRNA) were traded, and its beta was 1.71. Most recently the company’s share price was $137.75, and it changed around $11.01 or 8.69% from the last close, which brings the market valuation of the company to $52.13B. MRNA currently trades at a discount to its 52-week high of $217.25, offering almost -57.71% off that amount. The share price’s 52-week low was $115.03, which indicates that the current value has risen by an impressive 16.49% since then. We note from Moderna Inc.’s average daily trading volume that its 10-day average is 3.12 million shares, with the 3-month average coming to 3.50 million.

Moderna Inc. (NASDAQ:MRNA) trade information

Instantly MRNA has showed a green trend with a performance of 8.69% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 139.91 on Tuesday, 05/23/23 increased the stock’s daily price by 1.54%. The company’s shares are currently down -23.31% year-to-date, but still up 10.10% over the last five days. On the other hand, Moderna Inc. (NASDAQ:MRNA) is -0.28% up in the 30-day period. We can see from the shorts that 17.85 million shares have been sold at a short interest cover period of 5.1 day(s).

Moderna Inc. (MRNA) estimates and forecasts

Moderna Inc. share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -24.14 percent over the past six months and at a -114.46% annual growth rate that is well below the industry average of 11.20%. Moreover, analysts have decided to roll up on their fiscal year 2023 revenue estimates. The rating firms predict that it will loss -176.90% in revenue this quarter, and will report a decrease of -70.40% in the next quarter. The year-over-year growth rate is expected to be -60.70%, down from the previous year.

Consensus estimates provided by 11 financial analysts predict the company will bring in an average of $391.28 million in revenue for the current quarter. 12 analysts expect Moderna Inc. to make $2.47 billion in revenue for the quarter ending Sep 2023. The company’s sales for the same quarters a year ago were $4.75 billion and $3.36 billion respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -91.80%. Forecasts for the next quarter put sales growth at -26.60%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 92.10%.

MRNA Dividends

Moderna Inc.’s next quarterly earnings report is expected to be released around August 01 and August 07.

Moderna Inc. (NASDAQ:MRNA)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 9.61% of Moderna Inc. shares, and 68.33% of them are in the hands of institutional investors. The stock currently has a share float of 75.59%. Moderna Inc. stock is held by 1,538 institutions, with Baillie Gifford and Company being the largest institutional investor. By Mar 30, 2023, it held 12.19% of the shares, which is about 46.47 million shares worth $7.14 billion.

Vanguard Group, Inc. (The), with 7.22% or 27.53 million shares worth $4.23 billion as of Mar 30, 2023, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and Vanguard International Growth Fund were the top two Mutual Funds as of Dec 30, 2022. The former held 9.93 million shares worth $1.78 billion, making up 2.57% of all outstanding shares. On the other hand, Vanguard International Growth Fund held roughly 9.77 million shares worth around $1.72 billion, which represents about 2.53% of the total shares outstanding.